PERI-OPERATIVE CHEMOTHERAPY IN MUSCLE INVASIVE BLADDER CANCER: OVERVIEW AND A RATIONALE FOR THE NEED TO SEEK ALTERNATIVE TREATMENT: MAGNOLIA CLINICAL TRIAL

Onkourologiâ

I. A. Korneyev¹  R. Schipper²  W. Witjes²  P. Mulders²  C. Surcel³  L. Martínez-Piñeiro⁴  M. Colombel⁵  B. K. Komyakov⁶  P. Yakovlev⁷  P. Radziszewski⁸  V. B. Matveev⁹  B. Ya. Alekseev^1,10  O. I. Apolikhin^1,11  F. Witjes^1,12  R. Colombo^1,13  A. Heidenreich^1,14  M. Babjuk^1,15  I. A. Aboyan^1,16 

[1] Acad. I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of the Russian Federation;EAU Research Foundation, Arnhem;Fundeni Clinical Institute, Bucharest;Hospital Infanta Sofia, Madrid;Hôpital Edouard Herriot, Lyon;I.I. Mechnikov North-Western State Medical University, Ministry of Health of the Russian Federation, Saint Petersburg;Kiev Municipal Oncology Hospital, Kiev;Medical University Warsaw, Warsaw;N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow;P.A. Herzen Moscow Oncology Research Institute, Moscow;Research Institute of Urology, Ministry of Health of the Russian Federation, Moscow;UMC St. Radboud, Nijmegen;University Vita Salute San Raffaele Hospital, Milan;Universitätsklinikum der RWTH Aachen, Aachen;Urologická klinika FN Motol, Prague;Zdorovye (Health) Clinical Diagnostic Center, Nizhny Novgorod;

关键词: invasive bladder cancer;    cystectomy;    peri-operative chemotherapy;    magnolia clinical trial;    immunotherapy;   

DOI  :  10.17650/1726-9776-2013-9-4-71-74

来源: DOAJ

【 摘 要 】

The paper gives an overview of peri-operative chemotherapy in patients with muscle-invasive bladder cancer (MIBC) as insufficient option, demonstrates a clinical need for the development of more efficacious and safe treatment and introduces a MAGNOLIA study proposed by the European Association of Urology Research Fund in a concept of MIBC immunotherapy. The MAGNOLIA trial conducted in 56 research centers of 10 countries assesses whether adjuvant immunotherapy with recMAGE-A3+AS15 vaccine is safe and effective and improves outcome of patients with MAGE-A3 positive MIBC after cystectomy. 60 of 273 patients have been enrolled. The trial has to be continued to elaborate a general peri-operative treatment strategy for MIBC.

【 授权许可】

Unknown